QUALITY-OF-LIFE ASSESSMENT - PATIENT COMPLIANCE WITH QUESTIONNAIRE COMPLETION

被引:65
作者
SADURA, A
PATER, J
OSOBA, D
LEVINE, M
PALMER, M
BENNETT, K
机构
[1] QUEENS UNIV,NATL CANC INST CANADA,CLIN TRIALS GRP,82-84 BARRIE ST,KINGSTON K7L 3N6,ONTARIO,CANADA
[2] BRITISH COLUMBIA CANC AGCY,VANCOUVER,BC,CANADA
关键词
D O I
10.1093/jnci/84.13.1023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Previous investigators have found that compliance with quality-of-life data collection on cancer clinical trials is poor. There is general belief that collecting complete quality-of-life data is at present an unachievable goal. Purpose: We assessed the completeness of quality-of-life data collection on trials instituted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), since incorporation of quality-of-life outcomes into trials became mandatory for the group. Methods: Data from three NCIC CTG trials in which quality of life was a study end point were examined to determine the extent to which protocol specifications were met with respect to questionnaire completion. Two of the studies examined adjuvant therapies, and one examined anti-emetics. In two trials, the quality-of-life questionnaire of the European Organization for Research and Treatment of Cancer was used; in the other, the Breast Cancer Chemotherapy Questionnaire. Results: Patient compliance with questionnaire completion was unexpectedly high: More than 95% of the scheduled questionnaires were returned, and more than 99% of the questions were answered. Conclusions: We attribute this success to a comprehensive set of measures taken to enhance compliance on these studies. Which of these measures was most contributory requires further investigation, as does the issue of whether similar results can be obtained in other circumstances. Implications: It seems that the commonly held belief that quality-of-life data cannot be successfully collected in multicenter cancer trials is incorrect.
引用
收藏
页码:1023 / 1026
页数:4
相关论文
共 9 条
  • [1] Aaronson N, 1991, EFF CANC QUAL LIFE, P185
  • [2] 10-YEAR EXPERIENCE WITH CMF-BASED ADJUVANT CHEMOTHERAPY IN RESECTABLE BREAST-CANCER
    BONADONNA, G
    VALAGUSSA, P
    ROSSI, A
    TANCINI, G
    BRAMBILLA, C
    ZAMBETTI, M
    VERONESI, U
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1985, 5 (02) : 95 - 115
  • [3] IMPROVING THE QUALITY-OF-LIFE DURING CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - A COMPARISON OF INTERMITTENT AND CONTINUOUS TREATMENT STRATEGIES
    COATES, A
    GEBSKI, V
    BISHOP, JF
    JEAL, PN
    WOODS, RL
    SNYDER, R
    TATTERSALL, MHN
    BYRNE, M
    HARVEY, V
    GILL, G
    SIMPSON, J
    DRUMMOND, R
    BROWNE, J
    VANCOOTEN, R
    FORBES, JF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (24) : 1490 - 1495
  • [4] GANZ PA, 1988, CANCER, V61, P849, DOI 10.1002/1097-0142(19880215)61:4<849::AID-CNCR2820610435>3.0.CO
  • [5] 2-B
  • [6] QUALITY OF LIFE IN STAGE-II BREAST-CANCER - AN INSTRUMENT FOR CLINICAL-TRIALS
    LEVINE, MN
    GUYATT, GH
    GENT, M
    DEPAUW, S
    GOODYEAR, MD
    HRYNIUK, WM
    ARNOLD, A
    FINDLAY, B
    SKILLINGS, JR
    BRAMWELL, VH
    LEVIN, L
    BUSH, H
    ABUZAHRA, H
    KOTALIK, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) : 1798 - 1810
  • [7] LEVINE MN, 1991, EUR J CANCER S2, V27, pS39
  • [8] CHEMOTHERAPY CAN PROLONG SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER - REPORT OF A CANADIAN MULTICENTER RANDOMIZED TRIAL
    RAPP, E
    PATER, JL
    WILLAN, A
    CORMIER, Y
    MURRAY, N
    EVANS, WK
    HODSON, DI
    CLARK, DA
    FELD, R
    ARNOLD, AM
    AYOUB, JI
    WILSON, KS
    LATREILLE, J
    WIERZBICKI, RF
    HILL, DP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (04) : 633 - 641
  • [9] YANCIK R, 1989, Journal of Psychosocial Oncology, V7, P59